Virtual Library

Start Your Search

Élia Cipriano

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      205P - Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor (ID 478)

      12:30 - 13:00  |  Presenting Author(s): Élia Cipriano

      • Abstract


      Lung cancer has a high incidence in elderly patients. These patients are more predisposed to therapeutic toxicities, drug interactions and limitations due to physiologic alterations and comorbidities. The use of single-agent versus combination chemotherapy (ChT) as a first line treatment in this group of patients continues to be debated. The objective of this study is to characterise elderly patients diagnosed with lung cancer at our institution and evaluate overall survival (OS) in this population.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      This was a retrospective study of patients with first multidisciplinary discussion between 01/01/2015 and 31/12/2017, aged ≥ 70 years at the time of diagnosis and non-small cell cancer (NSCLC) histology. The population was characterized and a survival analysis (Kaplan-Meier; Log Rank test; statistical significance 5%) was performed, with a follow-up period until 30/11/2018.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      We identified 293 patients with lung cancer, 112 with an age ≥ 70 years (38,2%) and 98 of these patients (87,5%) with NSCLC histology. Fifty-three (54,1%) had an ECOG 0-1 and 25 (25,5%) an ECOG 2. At the time of diagnosis, 65 (66,3%) had stage IV, 9 (9,2%) stage III and 24 (24,5%) stage I-II. Forty-six patients (46,9%) were treated with systemic therapy (ST) due to locally advanced or stage IV disease; 24,5% (n=24) received surgery (with or without adjuvant ChT) or radiotherapy and 28,6% (n=28) received best supportive care (BSC). During a median follow-up of 30,9 months (mo.), median OS in patients treated with ST was 10,3 mo. (CI 95% 7,80-12,80), compared to 1,9 mo. (CI 95% 1,12-2,68) in patients receiving BSC, p < 0,0001. Regarding first line treatment in patients treated with ST, 22 (47,8%) received single-agent ChT, 16 (34,8%) received a doublet ChT, and 8 (17,4%) a tyrosine kinase inhibitor (TKI). Median OS was 8,3 mo. (CI 95% 3,70-12,90), 10,3 mo. (CI 95% 4,62-15,98) and 12,3 mo. (CI 95% 4,70 – 19,90), p=0,469, respectively.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      More than 1/3 of patients with lung cancer are elderly and nearly half of this population was treated with ST due to locally advanced or stage IV disease. Patients with advanced NSCLC receiving ST had a superior OS compared to patients receiving only BSC. The differences in OS between patients treated with single-agent, doublet ChT and TKI in first line were not statistical significant.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.